Nephrogen
Nephrogen Biotech is a company focused on developing curative genomic medicines for kidney and pancreatic diseases using an AI-driven platform called NeFINDTM. Their mission is to create effective treatments for serious diseases that are difficult to treat with current methods, aiming to improve longevity and quality of life for millions of Americans.
Industries
Nr. of Employees
small (1-50)
Nephrogen
New York, New York, United States, North America
Patents
Portable instrument for in vitro detection and quantification of biomarkers
US-10908156-B2
View Details
Portable instrument for in vitro detection and quantification of biomarkers
US-10908156-B2
View DetailsProducts
AI-driven gene delivery vector discovery platform
A platform that combines artificial intelligence with high-throughput in vivo screening to discover and optimize viral vectors for therapeutic gene delivery.
Web application for genome editing experiment design
An online tool to aid design and planning of genome editing experiments and workflows.
AI-driven gene delivery vector discovery platform
A platform that combines artificial intelligence with high-throughput in vivo screening to discover and optimize viral vectors for therapeutic gene delivery.
Web application for genome editing experiment design
An online tool to aid design and planning of genome editing experiments and workflows.
Services
Partnered development of vector-based genomic medicine programs with pharmaceutical sponsors and investors.
Partnered development of vector-based genomic medicine programs with pharmaceutical sponsors and investors.
Expertise Areas
- Gene delivery vector engineering
- High-throughput in vivo screening
- AI-driven therapeutic design
- Kidney- and pancreas-targeted delivery
Key Technologies
- AAV (adeno-associated virus) vector engineering
- Barcoded capsid libraries
- High-throughput in vivo selection
- AI-driven design/analysis
News & Updates
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids
Nature Communications December 30, 2024
Research Square August 16, 2024
HGTM March 14, 2024
JCI Insight November 14, 2019
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids
Nature Communications December 30, 2024
Research Square August 16, 2024
HGTM March 14, 2024
JCI Insight November 14, 2019